Please assess the completion status of the following clinical trial:

Trial Title: Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ≥ 18 years of age, with a confirmed diagnosis of cystic fibrosis~* Subjects with gating G551D CFTR mutation on at least one allele in the CFTR gene~* Subjects currently receiving treatment with ivacaftor on a stable regimen or not on a treatment regimen with ivacaftor, for at least 2 weeks prior to screening~* Weight ≥ 40.0 kg~* Subjects on stable concomitant treatment regimen for at least 4 weeks prior to baseline (excluding ivacaftor)~* Pre- or post-bronchodilator FEV1 ≥ 40% of predicted normal~* Subject will have to use highly effective contraceptive methods~Exclusion Criteria:~* On an ivacaftor-containing treatment regimen and unable or unwilling to discontinue ivacaftor for the washout and treatment periods of the study~* Concomitant use of antifungal drugs within 4 weeks of baseline~* A history of a clinically meaningful unstable or uncontrolled chronic disease~* Liver cirrhosis and portal hypertension~* Any significant change in the medical regimen for pulmonary health within 4 weeks of baseline~* Unstable pulmonary status or respiratory tract infection or changes in therapy for pulmonary disease within 4 weeks of baseline~* Abnormal liver function~* Clinically significant abnormalities on ECG~* History of malignancy, solid organ/haematological transplantation~* Abnormal renal function~* Participation in another experimental therapy study within 30 days or 5 times halflife

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLPG1837 dose 1, GLPG1837 dose 2, GLPG1837 dose 3 (Type: EXPERIMENTAL): GLPG1837 twice daily oral dosing - morning and evening, for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).